OSTEOPIL
Natural health product licensed in Canada
- Licence holder
- Nutreos BioSciences Inc.
- NPN or DIN-HM
- 80044308
- Status
- Active licence
- Licence date
- 22 August 2013
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Dioscorea villosa L.: Les matières premières végétales doivent avoir subi les étapes traditionnelles d'épluchage, de lavage et de traitement thermique. L'absence d'alcaloïdes et de composés cyanogènes doit être démontrée par des bulletins d'analyse.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Drynaria fortunei Source : Rhizome | 74.5 mg | Not calculated |
| Cullen corylifolium Source : Fruit extract Extraction ratio : 5:1 Dry plant equivalent : 240 mg | 48 mg | Not calculated |
| Dioscorea villosa Source : Root (standardized extract) Potency : 10 % Diosgenin | 48 mg | Not calculated |
| Ligustrum lucidum Source : Fruit (standardized extract) Potency : 5 % Iron | 48 mg | Not calculated |
| Cuscuta chinensis Source : Seed extract Extraction ratio : 5:1 Dry plant equivalent : 240 mg | 48 mg | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Maltodextrine, Dioxyde de silicium, Gélatine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Femmes en postménopause | Not specified | 2 Capsule | 1 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps to attenuate/reduce bone mineral density (BMD) loss in post-menopausal women when used in conjunction with adequate amounts of calcium and vitamin D.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 80044308
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.